Got $500? 2 Healthcare Stocks to Buy and Hold Forever
Abbott Laboratories provides exposure to multiple areas of healthcare.
AbbVie offers growth, income, and an attractive valuation.
10 stocks we like better than AbbVie ›
I don't know if we'll be riding in personal aircraft 20 years from now, like George Jetson did in the cartoon TV series. I don't know if artificial intelligence (AI) will replace millions of jobs. But there's one thing I'm quite confident about: We'll still need healthcare products and services in the future, whether we're talking about 10 or 100 years from now.
The healthcare sector is an ideal place for long-term investors to focus their attention, in my view. The trick is to find the stocks of companies that have demonstrated an ability to adapt to changes over multiple decades and are well-positioned to succeed going forward.
You won't need a fortune to get started investing in the healthcare sector. Got $500? Here are two healthcare stocks to buy and hold forever.
Abbott Laboratories (NYSE: ABT) was founded in 1888. Today, it ranks among the world's most successful healthcare companies and has a market cap of $240 billion. You can buy two shares of Abbott for around $276 and still have plenty left from an initial $500 to buy the second stock on the list.
That $276 will give you exposure to multiple healthcare areas. Abbott is a major force in the medical devices market, with products including the MitraClip mitral valve transcatheter edge-to-edge repair system and the FreeStyle Libre continuous glucose monitoring system. It's a top player in diagnostics, marketing products such as the Alinity family of diagnostic instruments.
The company is a leader in the nutritional products space, with top-selling brands including Ensure, PediaSure, and Similac. Abbott also operates a highly successful established pharmaceuticals business, marketing branded generic drugs such as Synthroid for treating hypothyroidism and biosimilars targeting cancer, women's health, and more indications.
This healthcare giant remains a nimble one. Abbott expects to grow its revenue in 2025 by 8% year over year at the midpoint of its guidance range. It's also continuing a long track record of innovation. For example, the company recently won the European CE Mark for the Volt PFA System for treating atrial fibrillation, and it's conducting a pivotal clinical trial for a new coronary intravascular lithotripsy system.
On top of all that, Abbott is a Dividend King. The company has increased its dividend for an impressive 53 consecutive years.
You might notice something similar about Abbott's and AbbVie's (NYSE: ABBV) names. That's no coincidence. Abbott spun off AbbVie as a separate business in 2013, but gave the new company a part of its name.
AbbVie has eclipsed the success of its parent. The big biopharmaceutical company sports a market cap of around $328 billion. It generated sales of $56.3 billion last year, versus less than $42 billion for Abbott. And with AbbVie's share price hovering around $185, you should be able to scoop up one share in addition to your two shares of Abbott and still have some cash left over.
The thing I like most about AbbVie is its resilience. In early 2023, the company lost U.S. exclusivity for its top-selling product, Humira. But AbbVie was well-prepared for this big blow. It had invested heavily in internal research and development, and made multiple acquisitions to bolster its pipeline.
Today, AbbVie's product lineup includes two successors to Humira, Rinvoq and Skyrizi, that should rake in combined sales of $31 billion by 2027. That's much higher than Humira's peak annual sales of around $22 billion.
Another thing I really like about AbbVie is its dividend. It inherited Abbott's streak of dividend increases and extended it. Since the 2013 spin-off, AbbVie has increased its dividend every year by a cumulative 310%. The company's forward dividend yield is a lofty 3.51%.
As an added bonus, the stock is relatively cheap. AbbVie's shares trade at only 15.2 times forward earnings. With more growth on the way from Rinvoq and Skyrizi, as well as other products, the stock's valuation is even more attractive.
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and AbbVie wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $704,676!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $950,198!*
Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 175% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of June 23, 2025
Keith Speights has positions in AbbVie. The Motley Fool has positions in and recommends AbbVie and Abbott Laboratories. The Motley Fool has a disclosure policy.
Got $500? 2 Healthcare Stocks to Buy and Hold Forever was originally published by The Motley Fool
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Scott Galloway Reached His Financial Goal 8 Years Ago. He Says There's Just No Justification For Becoming A Billionaire
Scott Galloway had a plan: sell his company, take $25 million, raise another $250 million, and become a billionaire. But then he stopped to think about it. 'Why would I want back on this hamster wheel of stress?' he asked on a recent episode of his podcast, 'Office Hours.' Galloway, a business professor, entrepreneur and investor, said he realized the pursuit of more wealth would just cost him time, peace of mind and family moments. 'I've been doing nothing but working for a quarter century,' he said. After hitting his personal financial target, he made a different choice: spend on what brings joy, pay people well, and give the rest away. 'I hit my number eight years ago,' he said. 'And I decided there's just no reason why I would ever need to be a billionaire.' Don't Miss: Peter Thiel turned $1,700 into $5 billion—now accredited investors are eyeing this software company with similar breakout potential. Learn how you can invest with $1,000 at just $0.30/share. Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Back a bold new approach to cancer treatment with high-growth potential. 'Every year I look at my number,' he explained. 'Anything above that number, I do one of two things: I either spend it or I give it away.' He added, 'It feels amazing to spend money and to give it away.' He owns a plane and refuses to let money prevent him from enjoying life. When friends can't afford to join, he covers the cost himself, saying it gives him satisfaction. His shift in mindset mirrors that of Andrew Wilkinson, a Canadian entrepreneur who told his own story in the 2024 book, 'Never Enough.' Wilkinson became a billionaire after building the tech conglomerate Tiny, but eventually saw the limits of wealth. After nearly partnering with legendary investor Charlie Munger, Wilkinson said he turned it down. The thought of chasing another level of wealth no longer appealed to him. Both Wilkinson and Galloway reached a similar conclusion. Once you have enough, more doesn't necessarily improve your life. In fact, it can increase stress. Trending: GoSun's Breakthrough Rooftop EV Charger Already Has 2,000+ Units Reserved — Become an Investor in This $41.3M Clean Energy Brand Today Galloway recalls the fear he felt in 2008 when his first son was born during the financial crisis. 'All I felt was shame and fear,' he said. 'I thought, I've failed this kid. I don't have enough money.' That fear stayed with him until he reached financial security. 'Happiness is not only a function of the things you have,' he said. 'It's a function of the things that you don't have—specifically, an absence from stress.' Galloway also wants to normalize open conversations about money. 'This zeitgeist that you're not supposed to talk about money is nothing but an effort by rich people to keep the poor and middle class down,' he said. He encourages people to share information about salaries, taxes and financial tools to help each other get ahead. 'Talking about it a lot gives you ideas and opportunities and can be quite cathartic,' he said. These days, Galloway says he's off the hamster wheel for good. He spends on joy, gives generously and says he finally feels free. Read Next: Maximize saving for your retirement and cut down on taxes: Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation. Are you rich? Here's what Americans think you need to be considered 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article Scott Galloway Reached His Financial Goal 8 Years Ago. He Says There's Just No Justification For Becoming A Billionaire originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Sign in to access your portfolio
Yahoo
24 minutes ago
- Yahoo
7.3% and 8.6% yields! 2 dividend shares to consider in July to target a £1,200 passive income
Though the FTSE 100 and FTSE 250 remain on prolonged bull runs, many top UK shares continue to offer great value. The environment is especially attractive for investors seeking high-yield dividend shares to buy. Here are just two great dividend stocks with sky-high dividend yields to consider: Dividend share Forward dividend yield Supermarket Income REIT (LSE:SUPR) 7.3% Greencoat UK Wind (LSE:UKW) 8.6% Of course dividends are never guaranteed. But if broker forecasts prove accurate, a £15,000 lump sum spread equally across these companies will provide a near-£2k second income over the next 12 months alone (£1,193 to be exact). I'm confident too that each of these dividend shares will steadily grow the passive income they deliver over time. Here's why. As a real estate investment trust (REIT), this business is set up to deliver a consistent stream of dividends to shareholders. At least nine-tenths of profits from their rental earnings must be paid out each year under sector rules. Supermarket Income owns and lets 81 stores to the stable grocery industry's big beasts like Tesco and Sainsbury. This ensures a steady flow of income that's not vulnerable to changes in the economic cycle. As you may expect, the business is mindful of the growth of online retail and the threat this poses to future property demand. According to Statista, online penetration rates for food and other groceries in the UK have more than doubled since 2016. Consequently, the company's investment strategy is focused on so-called omnichannel stores that 'provide in-store shopping, but also operate as last mile, online grocery fulfilment centres for both home delivery and click and collect'. This helps to greatly reduce (if not totally eliminate) the threat of click-based shopping. I'm more concerned about the impact of future inflation on the business. A subsequent pickup in interest rates could dent earnings and pull its share price sharply lower again. But I feel the potential rewards of owning the REIT's shares outweigh this danger. Annual dividends have risen each year since it listed on the London stock market in 2017. Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice. Renewable energy providers like Greencoat UK Wind, on the other hand, have a rapidly growing market to capitalise on. The climate's especially favourable in the UK, with the current government putting Net Zero among its policy priorities. For dividend investors, this fellow FTSE 250 REIT has other attractive qualities. Due to the stable nature of electricity demand, cash generation isn't impacted by broader economic conditions like many other UK shares. What's more, its revenues are essentially guaranteed by long-term contracts with energy suppliers. This has resulted in annual dividend growth that, except for last year when payouts were frozen, goes back to when the company joined the London Stock Exchange in 2013. That's not to say Greencoat UK Wind isn't without risk, of course. Like that other REIT I've described, profits are sensitive to interest rate changes. With just 49 wind farms on its books too, it doesn't enjoy technological diversification that can protect earnings when the wind doesn't blow. That said, on balance, I think its other safe-haven qualities — allied with that 8%+ dividend yield — make it worth serious consideration today. The post 7.3% and 8.6% yields! 2 dividend shares to consider in July to target a £1,200 passive income appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended Greencoat Uk Wind Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
What Happens to Your Joints When You Take Collagen
Reviewed by Dietitian Maria Laura Haddad-GarciaCollagen supplements may support joints, but more research is needed to confirm their effectiveness. Type II collagen is key for joint health, especially as we age and cartilage breaks down. Diet, exercise and weight management are proven ways to protect and support your feel it every time you go up the stairs, type an email or even make a delicious dinner—joint pain can touch almost every part of your day. It can affect just about anyone, at any time, depending on where and how it shows up. But what if there was a simple way to ease the ache—or even prevent it in the first place? According to some experts and social media, collagen can be it. So, does it actually work? In the early 2000s, that 'miracle fix' seemed to be glucosamine and chondroitin. Though the combo is still commercially available and many swear by its benefits, many studies have shown that it may not make a significant difference when it comes to treating osteoarthritis. Fast-forward today, and collagen supplements are stealing the spotlight—thanks in part to social media influencers who tout them with great aplomb. While collagen is typically known for its skin and hair benefits, many users are also turning to it for joint health. Still, there are plenty of voices in the mix for that, too. So, what's the real story? Can collagen truly help keep your joints feeling strong? We dug into the research and spoke with orthopedic surgeon Sean Peden, M.D., who specializes in foot and ankle care but has a broad understanding of orthopedics. 'Everybody's looking for something that's going to affect the future,' he explains. 'And I think there's some promise, both from a research and from a theoretical point of view. There are reasons to believe in it, so I think that's why it's getting popular.' Collagen is the most abundant protein in the body—making up around 30% of the total protein in most mammals. There are 28 known types of collagen, but about 90% of it is Type I, which is found in skin, bones, muscles and connective tissue. Type II collagen, however, plays a key role in joint health. 'Type II collagen, which is a specialized form, is really what you find in articular cartilage, which means joints, and that's the one that probably were the most focused on as orthopedic surgeons, because that type, that cartilage and joints, has very little reparative capacity,' says Peden. In other words, once the collagen in your joints starts to break down (a natural part of aging), your body has a hard time restoring it. This can lead to familiar issues, such as stiffness, limited range of motion and chronic discomfort. 'Articular cartilage wear is equivalent to degenerative arthritis,' Peden explains. 'This kind of cartilage has very poor ability to heal itself, especially once we are fully grown. The breakdown becomes accelerated with age, and the risk increases with things like increased body mass and trauma. As we get older, this specific cartilage increases its water content, and the collagen becomes less organized and more vulnerable to damage.' So, where do supplements come in? The idea is that taking collagen—often in type II form—might encourage the body to produce more of it, helping to maintain or even rebuild cartilage. While there might be some promise, Peden says that 'Many doctors aren't gung-ho about recommending it, because the data is just not there.' For instance, a small 2016 study found that after three months of treatment, collagen with acetaminophen improved knee pain more effectively than acetaminophen alone—but the sample size was small (just 39 participants), so further research is needed. And one 2023 paper published in Nutrients notes that while 'available research suggests a clear link between collagen ingredient composition/chemical structure and mechanism of action/efficacy, further research is required, including well-designed studies, to assess the therapeutic potential of each collagen type and composition for each clinical condition.' In other words, there really isn't enough good research to back claims just yet. That said, Peden notes that collagen supplements are generally a safe product to take. If you want to try it, you'll typically find collagen in powders, capsules or liquid form. Many people prefer capsules because they don't like the flavor of liquids and powders. According to most brands, you notice any differences after taking it for 8 to 12 weeks. For most healthy people, there's little downside to trying collagen supplements. However, there are a few things to know before you start. Support it with other nutrients: Collagen synthesis relies on key vitamins and minerals, especially vitamin C, zinc and copper. Many supplements already include these, but a well-rounded, nutrient-rich diet will help, too. Know your source: Collagen can be derived from cows, pigs, fish and eggs. If you have allergies or dietary restrictions, read the label closely. Talk to your doctor: While collagen is considered safe—even during pregnancy—and has no significant known interactions with medications, it's always a good idea to check in with a healthcare provider before starting any new supplement. Eat more protein-rich foods: Peden recommends that anyone with a musculoskeletal injury consume sufficient protein. Remember, collagen is the most abundant protein in our body. 'When you eat a piece of chicken, you're going to get a decent amount of collagen in there,' he says. However, he cautions that some of that collagen doesn't get absorbed into your body. Still, eating highly collagenous foods like skin-on chicken, bone broths and whole fish, such as sardines, is a great way to get your collagen naturally. Exercise regularly: Both resistance and cardio workouts help stimulate collagen production. 'If you're using your muscles, the muscles are going to try to hypertrophy or get bigger,' says Peden. This helps with collagen production. If your joints are hurting, stick with low-impact exercises so they are achievable. Maintain a healthy weight: Of course, exercise will probably have this effect, but Peden says that one of the most evidence-based ways to improve joint health is by not putting excessive weight on them. In fact, reducing body fat is one of the most effective ways to prevent osteoarthritis. According to an older study, reducing body fat can reduce the mechanical and biochemical stressors that contribute to joint degeneration. Collagen supplements may offer some joint-friendly benefits—but they're not a cure-all. And while more science is needed to confirm this, taking a high-quality collagen product likely won't do harm. When choosing a supplement, make sure it's independently verified, since the FDA does not regulate them. And be sure to talk to a healthcare provider before starting to take one. Most importantly, don't let supplements replace what we do know works: eating a nutrient-rich diet, moving your body and maintaining a healthy weight. 'I think that the problem sometimes with supplements like this, or with any alternative treatments, is that they can kind of distract patients from the things that are evidence-based, that we know are good,' says Peden. But if you find that collagen does help you, you'll be at the forefront of a promising trend. Read the original article on EATINGWELL
